DrugBiological
Tumor Necrosis Factor-alpha clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 1992 (1)
| Year | Studies |
|---|---|
| 1992 | 1 |
| 1999 | 1 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
National Institutes of Health Clinical Center (CC) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Aarhus University Hospital (1) · National Cancer Institute (NCI) (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Tumor Necrosis Factor-alpha is read from its arms, and is right about nine times in ten.
Testing it · 5
- Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or LegCompletedPhase 2National Institutes of Health Clinical Center (CC)NCT00019968Written as tumor necrosis factor
- A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related ComplexCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001004Written as Tumor Necrosis Factor
- Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on Central Nervous System (CNS) Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?CompletedNot applicableAarhus University HospitalNCT01452958Written as TNF-alpha
- A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity MelanomaCompletedPhase 3National Cancer Institute (NCI)NCT00001296Written as tumor necrosis factor
- A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's SarcomaCompletedPhase 1University of California, San FranciscoNCT00002262Written as Tumor Necrosis Factor